{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:25Z","timestamp":1789549585255,"version":"build-2803163510"},"reference-count":65,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Fusion alterations have transformed outcomes for a subset of patients with nonsmall cell lung cancer (NSCLC), as part of the evolution of precision oncology. While the role of molecular pathology in the diagnosis and treatment of NSCLC has rapidly evolved, it remains the responsibility of the pulmonologist to coordinate the diagnostic evaluation of patients with lung cancer, including clinical assessment, obtaining a histological diagnosis and coordination of staging procedures. This review focuses on the biology, clinical significance and diagnostic considerations of fusion alterations in NSCLC. We summarise current knowledge regarding the role of actionable gene fusion translocations, including anaplastic lymphoma kinase (\n                    <jats:italic>ALK<\/jats:italic>\n                    )\n                    <jats:italic>,<\/jats:italic>\n                    ros-protooncogene 1 (\n                    <jats:italic>ROS1<\/jats:italic>\n                    )\n                    <jats:italic>,<\/jats:italic>\n                    retinoblastoma rearranged during transfection (\n                    <jats:italic>RET<\/jats:italic>\n                    ) and neurotrophic tyrosine receptor kinase (\n                    <jats:italic>NTRK)<\/jats:italic>\n                    fusions, while outlining clinical decision-making considerations and testing frameworks. For respiratory physicians, it is essential to prioritise suitable diagnostic modalities by taking into account tissue availability, turnaround time, and consideration of next generation sampling methods and noninvasive sampling such as blood-based circulating tumour DNA assays.\n                  <\/jats:p>","DOI":"10.1183\/20734735.0259-2025","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:20:20Z","timestamp":1789546820000},"page":"250259","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecules of lung cancer \u2013 fusion alterations in nonsmall cell lung cancer: biology and diagnostic considerations"],"prefix":"10.1183","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2744-6014","authenticated-orcid":false,"given":"Marie","family":"Talty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091601200928000_22.3.250259.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2026091601200928000_22.3.250259.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"2026091601200928000_22.3.250259.3","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0388-CP"},{"key":"2026091601200928000_22.3.250259.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"2026091601200928000_22.3.250259.5","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"2026091601200928000_22.3.250259.6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/gcc.23022","article-title":"Fusion-positive non-small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications","volume":"61","author":"Kazdal","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"2026091601200928000_22.3.250259.7","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.3390\/ijms26083802","article-title":"Oncogenic fusions in NSCLC: from mechanisms to clinical applications","volume":"26","author":"Theik","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026091601200928000_22.3.250259.8","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.21037\/tlcr-20-186","article-title":"Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy","volume":"9","author":"Suda","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026091601200928000_22.3.250259.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.12.001"},{"key":"2026091601200928000_22.3.250259.10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0020"},{"key":"2026091601200928000_22.3.250259.11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/diagnostics13061117","article-title":"NSCLC in the era of targeted and immunotherapy: what every pulmonologist must know","volume":"13","author":"Mitchell","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026091601200928000_22.3.250259.12","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"2026091601200928000_22.3.250259.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2026091601200928000_22.3.250259.14","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026091601200928000_22.3.250259.15","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.21037\/tlcr-20-676","article-title":"Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas","volume":"9","author":"Matter","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026091601200928000_22.3.250259.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3293"},{"key":"2026091601200928000_22.3.250259.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11058"},{"key":"2026091601200928000_22.3.250259.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38196-z"},{"key":"2026091601200928000_22.3.250259.19","first-page":"100627","article-title":"Genomic landscape of NSCLC in the Republic of Ireland","volume":"5","author":"Keogh","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2026091601200928000_22.3.250259.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102873"},{"key":"2026091601200928000_22.3.250259.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911793"},{"key":"2026091601200928000_22.3.250259.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-003035"},{"key":"2026091601200928000_22.3.250259.23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0050"},{"key":"2026091601200928000_22.3.250259.24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.21037\/tlcr-22-855","article-title":"A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma","volume":"12","author":"Hernandez","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2026091601200928000_22.3.250259.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"2026091601200928000_22.3.250259.26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtho.2025.02.021","article-title":"First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: five-year outcomes from the CROWN study","volume":"20","author":"Wu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026091601200928000_22.3.250259.27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0231"},{"key":"2026091601200928000_22.3.250259.28","unstructured":"Nuvalent, Inc . Nuvalent overview. Date last updated: 27 February 2024. https:\/\/filecache.investorroom.com\/mr5ir_nuvalent\/330\/Nuvalent%20Overview_February%2027%2C%202024_vFINAL.pdf"},{"key":"2026091601200928000_22.3.250259.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6345"},{"key":"2026091601200928000_22.3.250259.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302299"},{"key":"2026091601200928000_22.3.250259.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"2026091601200928000_22.3.250259.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.002"},{"key":"2026091601200928000_22.3.250259.33","doi-asserted-by":"crossref","first-page":"864666","DOI":"10.3389\/fonc.2022.864666","article-title":"NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"2026091601200928000_22.3.250259.34","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion\u2013positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026091601200928000_22.3.250259.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"2026091601200928000_22.3.250259.36","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.cllc.2018.12.017","article-title":"Durable clinical response to crizotinib in IRF2BP2-NTRK1 non\u2013small-cell lung cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2026091601200928000_22.3.250259.37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion\u2013positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091601200928000_22.3.250259.38","doi-asserted-by":"crossref","first-page":"250051","DOI":"10.1183\/20734735.0051-2025","article-title":"Liquid biopsy in lung cancer","volume":"21","author":"Toland","year":"2025","journal-title":"Breathe (Sheff)"},{"key":"2026091601200928000_22.3.250259.39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jtho.2025.05.014","article-title":"Safety and sample adequacy for comprehensive biomarker testing of bronchoscopic biopsies: an American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice Guideline","volume":"20","author":"Chaddha","year":"2025","journal-title":"J Thorac Onco"},{"key":"2026091601200928000_22.3.250259.40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5858\/arpa.2020-0119-CP","article-title":"Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: guideline from the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology","volume":"144","author":"Roy-Chowdhuri","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2026091601200928000_22.3.250259.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414059"},{"key":"2026091601200928000_22.3.250259.42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cllc.2014.06.005","article-title":"Diagnosis and predictive molecular analysis of non\u2013small-cell lung cancer in the Africa-middle east region: challenges and strategies for improvement","volume":"15","author":"Slavik","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"2026091601200928000_22.3.250259.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014"},{"key":"2026091601200928000_22.3.250259.44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.32074\/1591-951X-1015","article-title":"RNA-based next-generation sequencing in non-small cell lung cancer patients: data from Campania, Italy","volume":"116","author":"Pisapia","year":"2024","journal-title":"Pathologica"},{"key":"2026091601200928000_22.3.250259.45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jasc.2025.06.002","article-title":"Optimizing cytology and small biopsy specimen processing for ancillary studies: recommendations from the American society of cytopathology task force","volume":"14","author":"Roy-Chowdhuri","year":"2025","journal-title":"J Am Soc Cytopathol"},{"key":"2026091601200928000_22.3.250259.46","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207825"},{"key":"2026091601200928000_22.3.250259.47","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21899"},{"key":"2026091601200928000_22.3.250259.48","unstructured":"National Comprehensive Cancer Network (NCCN) . Non-small cell lung cancer. Version 5. 2023. NCCN Clinincl Practice Guideline. Plymouth Meeting, National Comprehensive Cancer Network (NCCN), 2023."},{"key":"2026091601200928000_22.3.250259.49","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026091601200928000_22.3.250259.50","doi-asserted-by":"crossref","first-page":"115582","DOI":"10.1016\/j.ejca.2025.115582","article-title":"Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: the PLAN study","volume":"225","author":"O'Reilly","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026091601200928000_22.3.250259.51","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2021.39.15_suppl.9011","article-title":"Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: analysis from the CROWN study","volume":"39","author":"Soo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026091601200928000_22.3.250259.52","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/1878-0261.13468","article-title":"Detecting ALK, ROS1, and RET fusions and the MET\u0394ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques","volume":"17","author":"Gim\u00e9nez-Capit\u00e1n","year":"2023","journal-title":"Mol Oncol"},{"key":"2026091601200928000_22.3.250259.53","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2217\/pgs-2021-0048","article-title":"Methods for actionable gene fusion detection in lung cancer: now and in the future","volume":"22","author":"Pisapia","year":"2021","journal-title":"Pharmacogenomics"},{"key":"2026091601200928000_22.3.250259.54","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.3390\/cancers15092425","article-title":"Circulating tumour DNA (ctDNA) as a predictor of clinical outcome in non-small cell lung cancer undergoing targeted therapies: a systematic review and meta-analysis","volume":"15","author":"Zaman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091601200928000_22.3.250259.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"key":"2026091601200928000_22.3.250259.56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/diagnostics14040399","article-title":"Robotic-assisted bronchoscopy: a comprehensive review of system functions and analysis of outcome data","volume":"14","author":"Prado","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026091601200928000_22.3.250259.57","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2022.04.013","article-title":"Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel","volume":"168","author":"Ryan","year":"2022","journal-title":"Lung Cancer Amst Neth"},{"key":"2026091601200928000_22.3.250259.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.033"},{"key":"2026091601200928000_22.3.250259.59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirol Carlton Vic"},{"key":"2026091601200928000_22.3.250259.60","doi-asserted-by":"crossref","first-page":"102348","DOI":"10.1016\/j.tranon.2025.102348","article-title":"Molecular profile of non-small cell lung cancer in a predominantly Black African population in Kenya: a single institution review","volume":"55","author":"Mwanzi","year":"2025","journal-title":"Transl Oncol"},{"key":"2026091601200928000_22.3.250259.61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12920-024-01795-w","article-title":"Whole genome sequencing in clinical practice","volume":"17","author":"Bagger","year":"2024","journal-title":"BMC Med Genomics"},{"key":"2026091601200928000_22.3.250259.62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026091601200928000_22.3.250259.63","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2021.0042"},{"key":"2026091601200928000_22.3.250259.64","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28482"},{"key":"2026091601200928000_22.3.250259.65","doi-asserted-by":"crossref","first-page":"107839","DOI":"10.1016\/j.pec.2023.107839","article-title":"Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives","volume":"114","author":"Pack","year":"2023","journal-title":"Patient Educ Couns"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0259-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:20:26Z","timestamp":1789546826000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0259-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/20734735.0259-2025"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0259-2025","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}